Chemotherapy-induced nausea and vomiting (CINV) is one of the most debilitating toxicities associated with cancer treatment. Although effective antiemetic agents are available, their use in practice often is suboptimal.
Methods
The author reviews the pathophysiology of CINV as well as the drug classes and cost considerations that should be incorporated into treatment planning.
Results
Several drug classes, including 5-hydroxytryptamine-3 receptor antagonists, neurokinin-1 receptor antagonists, and corticosteroids, are effective, especially when used in combination. Older antiemetic agents, such as prochlorperazine and metoclopramide, as well as olanzapine may provide reasonable alternatives in certain settings.
Conclusions
Interventions for CINV should include standard-of-care antiemetics combined with corticosteroids. The cost of using older, less expensive antiemetics may be outweighed by the expenditures to rescue patients after suboptimal prophylaxis, as well as the indirect costs of missed work and lost productivity.
References
1.
CohenL., de MoorC.A., EisenbergP., MingE.E., HuH.. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.Support Care Cancer.2007; 15(5): 497–503.
2.
HaideraliA., MendittoL., GoodM., TeitelbaumA., WegnerJ.. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population.Support Care Cancer.2011; 19(6): 843–851.
3.
Bloechl-DaumB., DeusonR.R., MavrosP., HansenM., HerrstedtJ.. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.J Clin Oncol.2006; 24(27): 4472–4478.
4.
BallatoriE., RoilaF., RuggeriB.. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.Support Care Cancer.2007; 15(2): 179–185.
5.
HilariusD.L., KloegP.H., van der WallE., van den HeuvelJ.J., GundyC.M., AaronsonN.K.. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.Support Care Cancer.2012; 20(1): 107–117.
6.
BorisonH.L., WangS.C.. Functional localization of central coordinating mechanism for emesis in cat.J Neurophysiol.1949; 12(5): 305–313.
7.
BorisonH.L., WangS.C.. Physiology and pharmacology of vomiting.Pharmacol Rev.1953; 5(2): 193–230.
8.
BorisonH.L., BorisonR., McCarthyL.E.. Phylogenic and neurologic aspects of the vomiting process.J Clin Pharmacol.1981; 21(8-9 suppl): 23S–29S.
9.
HeskethP.J.. Chemotherapy-induced nausea and vomiting.N Engl J Med.2008; 358(23): 2482–2494.
10.
LohrL.. Chemotherapy-induced nausea and vomiting.Cancer J.2008; 14(2): 85–93.
11.
FrameD.G.. Best practice management of CINV in oncology patients: I. physiology and treatment of CINV: multiple neurotransmitters and receptors and the need for combination therapeutic approaches.J Support Oncol.2010; 8(2 suppl 1): 5–9.
12.
HeskethP.J., Van BelleS., AaproM.. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.Eur J Cancer.2003; 39(8): 1074–1080.
13.
DarmaniN.A., CrimJ.L., JanoyanJ.J., AbadJ., RamirezJ.. A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew.Brain Res.2009; 1248: 40–58.
14.
DarmaniN.A., CheboluS., AmosB., AlkamT.. Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva).Pharmacol Biochem Behav.2011; 99(4): 573–579.
15.
RojasC., LiY., ZhangJ.. The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo.J Pharmacol Exp Ther.2010; 335(2): 362–368.
16.
GershonM.D.. Review article: serotonin receptors and transporters—roles in normal and abnormal gastrointestinal motility.Aliment Pharmacol Ther.2004; 20(suppl 7): 3–14.
17.
BlackshawL.A., BrookesS.J., GrundyD., SchemannM.. Sensory transmission in the gastrointestinal tract.Neurogastroenterol Motil.2007; 19(suppl 1): 1–19.
18.
BurkeC.W., MasonJ.N., SurmanS.L.. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy.PLoS Pathog.2011; 7(7): e1002134.
19.
LesurtelM., SollC., GrafR., ClavienP.A.. Role of serotonin in the hepatogastrointestinal tract: an old molecule for new perspectives.Cell Mol Life Sci.2008; 65(6): 940–952.
20.
FärberL., HausU., SpäthM., DrechslerS.. Physiology and pathophysiology of the 5-HT3 receptor.Scand J Rheumatol Suppl.2004; 119: 2–8.
21.
EndoT., HamaueN., IhiraE.. Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model.Res Comm Mol Pathol Pharmacol.2002;111(1-4): 55–68.
22.
CabezosP.A., VeraG., Martin-FontellesM.I., Fernández-PujolR., AbaloR.. Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat: comparison with pica.Neurogastroenterol Motil.2010; 22(7): 797–805, e224–e225.
23.
DiemunschP., GrélotL.. Potential of substance P antagonists as antiemetics.Drugs.2000; 60(3): 533–546.
24.
HuskeyS.E., DeanB.J., BakhtiarR.. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets.Drug Metab Dispos.2003; 31(6): 785–791.
25.
MoertelC.G., ReitemeierR.J., GageR.P.. A controlled clinical evaluation of antiemetic drugs.JAMA.1963; 186: 116–118.
26.
BaschE., PrestrudA.A., HeskethP.J.. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.J Clin Oncol.2011; 29(31): 4189–4198.
27.
NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 1.2012. National Comprehensive Cancer Network. http://www.nccn.org. Accessed February 22, 2012.
28.
RoilaF., HerrstedtJ., AaproM.. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Ann Oncol.2010; 21(suppl 5): v232–v243.
29.
RoscoeJ.A., BushunowP., MorrowG.R.. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma.Cancer.2004; 101(11): 2701–2708.
30.
FioreJ.J., GrallaR.J.. Pharmacologic treatment of chemotherapy-induced nausea and vomiting.Cancer Invest.1984; 2(5): 351–361.
31.
De MulderP.H., SeynaeveC., VermorkenJ.B.. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study.Ann Intern Med.1990; 113(11): 834–840.
32.
FeyerP., JordanK.. Update and new trends in antiemetic therapy: the continuing need for novel therapies.Ann Oncol.2011; 22(1): 30–38.
33.
JordanK., HinkeA., GrotheyA.. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.Support Care Cancer.2007; 15(9): 1023–1033.
34.
de WitR., AaproM., BlowerP.R.. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?Cancer Chemother Pharmacol.2005; 56(3): 231–238.
35.
WongE.H., ClarkR., LeungE.. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.Br J Pharmacol.1995; 114(4): 851–859.
36.
RubensteinE.B.. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.Clin Adv Hematol Oncol.2004(5); 2: 284–289.
37.
BotrelT.E., ClarkO.A., ClarkL., PaladiniL., FaleirosE., PegovettiB.. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.Support Care Cancer.2011; 19(6): 823–832.
38.
LikunZ., XiangJ., YiB., XinD., TaoZ.L.. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.Oncologist.2011; 16(2): 207–216.
DeckerG.M., DeMeyerE.S., KiskoD.L.. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.J Support Oncol.2006; 4(1): 35–41, 52.
HowellJ., SmeetsJ., DrenthH.J., GillD.. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting.J Oncol Pharm Pract.2009; 15(4): 223–231.
44.
IoannidisJ.P., HeskethP.J., LauJ.. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence.J Clin Oncol.2000; 18(19): 3409–3422.
45.
GrunbergS.M.. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis.Ann Oncol.2007; 18(2): 233–240.
46.
ChawlaS.P., GrunbergS.M., GrallaR.J.. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Cancer.2003; 97(9): 2290–2300.
47.
HeskethP.J., AaproM., StreetJ.C., CaridesA.D.. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.Support Care Cancer.2010; 18(9): 1171–1177.
48.
GrunbergS., ChuaD., MaruA.. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE.J Clin Oncol.2011; 29(11): 1495–1501.
49.
LindleyC., GoodinS., McCuneJ.. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.Am J Clin Oncol.2005; 28(3): 270–276.
NavariR.M., EinhornL.H., LoehrerPJSr. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.Support Care Cancer.2007; 15(11): 1285–1291.
52.
NavariR.M., GrayS.E., KerrA.C.. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.J Support Oncol.2011; 9(5): 188–195.
53.
RamseyS.D., FedorenkoC.R., SnellK.S.. Cancer diagnosis as a risk factor for personal bankruptcy.ASCO Annual Meeting Abstracts.2011; 29: 6007.
54.
BurkeT.A., WisniewskiT., ErnstF.R.. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.Support Care Cancer.2011; 19(1): 131–140.
55.
MolassiotisA., HelinA.M., DabbourR., HummerstonS.. The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients.Complement Ther Med.2007; 15(1): 3–12.
56.
RyanJ.L., HecklerC.E., RoscoeJ.A.. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.Support Care Cancer.2011 Aug 5. Epub ahead of print.
57.
ZickS.M., RuffinM.T., LeeJ.. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting.Support Care Cancer.2009; 17(5): 563–572.
